In September 2022, i3 Health conducted a survey of 157 oncology nurses at the Greater Los Angeles Oncology Nursing Society (GLAONS) 6th Annual Oncology Care Summit to assess nurses' familiarity with and desire to understand novel oncology treatment options, including chimeric antigen receptor (CAR) T-cell therapies, cyclin-dependent kinase (CDK)4/6 inhibitors, immune checkpoint inhibitors, poly-ADP ribose polymerase (PARP) inhibitors, and antibody-drug conjugates. CAR T-cell therapy has been sho...